share_log
Reuters ·  Dec 12, 2024 08:15
Pfizer’s Ibrance® in Combination With Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 Patina Study in Patients With Hr+, Her2+ Metastatic Breast Cancer
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment